Equillium has initiated a Phase 1 clinical trial for its novel drug EQ504, targeting autoimmune and inflammatory diseases, with proof-of-mechanism data expected in Q2 2027. The trial, conducted in Australia, will assess safety and biological activity in healthy participants. The company secured $20 million in financing, boosting its cash to $72 million pro forma, supporting operations through 2029. Pending positive results, Equillium plans a proof-of-concept study in ulcerative colitis patients in late 2027.
Equillium's recent corporate and clinical updates provide context for health sector investors. For readers following the health sector, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced US health stocks, 23 rose and 124 fell today. Notable movers include BNGO at USD 1.00 with a 1-day change of -9.09%, FLNA at USD 0.44 down 8.71%, and RLAY at USD 18.16 down 7.91%.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
